This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing advanced solid malignancies.
Ask a Question?
Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others
Please enter valid email address.
Please enter all required fields.